MediWound (NASDAQ:MDWD) Stock Passes Below Two Hundred Day Moving Average - What's Next?

Key Points

• MediWound shares fell below their 200-day moving average, reaching $13.19 before closing near $13.47, compared with the 200-day average of $15.27.
• Analyst sentiment is mixed: the stock carries an overall “Hold” rating with an average price target of $33.00, although Oppenheimer cut its target to $30 while maintaining an “Outperform” rating.
• The company reported a quarterly loss of $0.77 per share, slightly missing estimates, despite revenue of $3.09 million exceeding expectations; MediWound continues to post steep negative margins and analysts expect a full-year loss.

MediWound Ltd. (NASDAQ:MDWD - Get Free Report) shares passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $15.27 and traded as low as $13.19. MediWound shares last traded at $13.47, with a volume of 80,527 shares traded.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. Oppenheimer reaffirmed an "outperform" rating and issued a $30.00 price objective (down from $32.00) on shares of MediWound in a research note on Friday, August 14th. Wall Street Zen downgraded shares of MediWound from a "sell" rating to a "strong sell" rating in a research report on Saturday, August 15th. Weiss Ratings lowered shares of MediWound from a "sell (d-)" rating to a "sell (e+)" rating in a report on Tuesday, September 8th. Finally, HC Wainwright restated a "buy" rating and issued a $36.00 price target on shares of MediWound in a research report on Thursday, May 28th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, MediWound currently has an average rating of "Hold" and an average target price of $33.00.

MediWound Stock Performance

The stock has a fifty day simple moving average of $13.80 and a two-hundred day simple moving average of $15.27. The stock has a market capitalization of $173.09 million, a price-to-earnings ratio of -7.48 and a beta of 0.14.

MediWound (NASDAQ:MDWD - Get Free Report) last announced its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.01). MediWound had a negative net margin of 170.10% and a negative return on equity of 47.24%. The business had revenue of $3.09 million during the quarter, compared to analyst estimates of $2.59 million. Research analysts forecast that MediWound Ltd. will post -2.31 earnings per share for the current year.

Insider Transactions at MediWound

In other MediWound news, COO Shmuel Hess sold 3,958 shares of the business's stock in a transaction that occurred on Thursday, August 27th. The stock was sold at an average price of $12.92, for a total value of $51,137.36. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 9.20% of the company's stock.

Institutional Trading of MediWound

Hedge funds have recently modified their holdings of the stock. Clal Insurance Enterprises Holdings Ltd boosted its stake in MediWound by 22.8% during the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 71,000 shares of the biopharmaceutical company's stock worth $1,311,000 after acquiring an additional 13,196 shares in the last quarter. UBS Group AG increased its stake in MediWound by 90.1% in the fourth quarter. UBS Group AG now owns 145,057 shares of the biopharmaceutical company's stock valued at $2,678,000 after purchasing an additional 68,756 shares in the last quarter. Finally, Silverberg Bernstein Capital Management LLC increased its stake in MediWound by 8.7% in the first quarter. Silverberg Bernstein Capital Management LLC now owns 200,005 shares of the biopharmaceutical company's stock valued at $3,222,000 after purchasing an additional 16,081 shares in the last quarter. Institutional investors own 46.83% of the company's stock.

About MediWound

MediWound Ltd. NASDAQ: MDWD is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative enzymatic therapies for tissue injury and wound care. The company's products are designed to remove damaged or nonviable tissue while helping preserve healthy tissue, supporting wound management and healing.

MediWound's lead commercial product is NexoBrid, a topical bromelain-based therapy used for the enzymatic removal of eschar in adults with deep partial-thickness and full-thickness thermal burns.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.